Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice

Table 1 Specific heart failure patient subgroups representing a challenge for the implementation of LCZ696 in clinical practice

Clinical characteristics	Marginally low blood pressure
	Hospitalization for AHF
	NYHA IV class
	Advanced heart failure
Drug therapy-related characteristics	ACEi-naïve patients
	Intolerance to ACEi or ARB
	Low ACEi dose
	High ACEi dose
	Patients on ARBs therapy

ACEi, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; NYHA, New York Heart Association.

ISSN: 1741-7015